Acute activation, desensitization and smoldering activation of human acetylcholine receptors.

Barbara Campling, M.D., FRCPC
*Thomas Jefferson University Hospital*, barbara.campling@jefferson.edu

Alexander Kuryatov
*Thomas Jefferson University Hospital*

Jon Lindstrom
*Thomas Jefferson University Hospital*

---

Let us know how access to this document benefits you

Follow this and additional works at: [http://jdc.jefferson.edu/department_neuroscience](http://jdc.jefferson.edu/department_neuroscience)

Part of the [Medicine and Health Sciences Commons](http://jdc.jefferson.edu/department_neuroscience)

---

Recommended Citation
http://jdc.jefferson.edu/department_neuroscience/8

---

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Neuroscience by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Acute Activation, Desensitization and Smoldering Activation of Human Acetylcholine Receptors

Barbara G. Campling1,2, Alexander Kuryatov1, Jon Lindstrom1*

1 Department of Neuroscience, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, 2 Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America

Abstract

The behavioral effects of nicotine and other nicotinic agonists are mediated by AChRs in the brain. The relative contribution of acute activation versus chronic desensitization of AChRs is unknown. Sustained “smoldering activation” occurs over a range of agonist concentrations at which activated and desensitized AChRs are present in equilibrium. We used a fluorescent dye sensitive to changes in membrane potential to examine the effects of acute activation and chronic desensitization by nicotinic AChR agonists on cell lines expressing human α4β2, α3β4 and α7 AChRs. We examined the effects of acute and prolonged application of nicotine and the partial agonists varenicline, cytisine and sazetidine-A on these AChRs. The range of concentrations over which nicotine causes smoldering activation of α4β2 AChRs was centered at 0.13 μM, a level found in smokers. However, nicotine produced smoldering activation of α3β4 and α7 AChRs at concentrations well above levels found in smokers. The α4β2 expressing cell line contains a mixture of two stoichiometries, namely (α4β2)2β2 and (α4β2)2β4. The (α4β2)2β2 stoichiometry is more sensitive to activation by nicotine. Sazetidine-A activates and desensitizes only this stoichiometry. Varenicline, cytisine and sazetidine-A were partial agonists on this mixture of α4β2 AChRs, but full agonists on α3β4 and α7 AChRs. It has been reported that cytisine and varenicline are most efficacious on the (α4β2)2β4 stoichiometry. In this study, we distinguish the dual effects of activation and desensitization of AChRs by these nicotinic agonists and define the range of concentrations over which smoldering activation can be sustained.

Introduction

The component of tobacco that drives its compulsive use is nicotine, an alkaloid that acts on nicotinic acetylcholine receptors (AChRs) in the brain. AChRs are a heterogeneous family of ligand-gated cation channels which consist of five homologous subunits arranged around a central pore [1,2]. They are heteropentamers formed of combinations of α and β subunits, or homopentamers formed of 5α′7 subunits [3]. Heteromeric AChRs usually have two ACh binding sites that are formed between adjacent α and β subunits. The remaining subunit is in the “accessory” position. While the accessory subunit does not usually form part of a binding site for ACh, it has major effects on responses to nicotinic agonists, antagonists and allosteric modulators. There is a third ACh binding site in the α4β2β4 stoichiometry, formed at the interface between the α4 accessory subunit and another α4 subunit [4,5].

The predominant AChR subtypes in human brain are heteromeric AChRs comprised of combinations of α4 and β2 subunits, alone or in combination with other subunits, such as β3, α5 or α6, or homomeric AChRs comprised of α7 subunits. Self-administration of nicotine is inhibited by knockout of α4, β2, or α6 subunits [6], but is increased by knockout of α5 subunits [7]. AChRs containing the α5 subunit are the predominant postsynaptic AChRs in the autonomic and enteric nervous systems [8]. In the brain, α3 and β4 subunits are prominent only in the medial habenula [9].

Although nicotine is a drug of abuse, it also has many positive effects that could be exploited therapeutically. In addition to their use for treating nicotine addiction, nicotinic agonists are being developed for treatment of disorders ranging from Alzheimer’s disease to schizophrenia [10]. Varenicline and cytisine have been promoted for treating nicotine addiction because they are high affinity partial agonists that displace nicotine and decrease its rewarding effects by attenuating dopamine release in the mesolimbic system [11]. However, many of the clinical effects of nicotine and partial agonists are mediated by desensitization of AChRs. Sazetidine-A is a very potent and high affinity acute agonist, and a very efficient desensitizer. It produces many of the in vivo effects of nicotine and partial agonists such as inhibition of nicotine self-administration, increased attention, pain relief, reduction in anxiety and depression, and weight reduction, suggesting that these effects may result more from desensitization than from activation [12–17].

All of these cholinergic ligands upregulate (α4β2)β2 AChRs in tissue culture, and all but sazetidine-A also do so in vivo [18]. Sazetidine-A may have sufficient membrane permeability in vivo to desensitize AChRs on neuron surfaces, but insufficient to achieve intracellular concentrations sufficient to promote assembly of (α4β2)β2 AChRs [18,19].
Transient application of nicotine or other agonists activates AChRs, opening the cation channel resulting in depolarization and other effects mediated by entry of cations, followed by acute desensitization and then rapid recovery. Chronic exposure to agonists causes prolonged desensitization. In typical physiological assays, the effects of these drugs are observed over seconds or minutes. However, in vivo they are present over many hours. “Smoldering activation” occurs at agonist concentrations at which some AChRs are desensitized while others are activated. This can occur within minutes after recovery from acute activation or after prolonged continuous exposure to agonists. The relative contributions of acute activation and chronic desensitization of AChRs in causing as well as treating nicotine addiction, or mediating the beneficial effects of nicotine are being actively investigated [18,20].

We have established a number of transfected cell lines that permanently express human AChR subtypes [21–25]. The α4β2 expressing cell line contains a mixture of two stoichiometries differing by the presence of α4 or β2 in the accessory position [22]. A similar mixture of stoichiometries is found in brain [26,27]. The (α4β2)2β2 stoichiometry is more sensitive to activation and upregulation by nicotine, desensitizes more slowly and is less permeable to calcium [22,23]. It is sensitive to activation by sazetidine-A, but not varenicline or cytisine, whereas the (α4β2)α4 stoichiometry is sensitive to activation by varenicline and cytisine but not sazetidine-A [29,30].

It is difficult to measure chronic desensitization of human AChRs using classical electrophysiological techniques such as human AChRs expressed in Xenopus oocytes or patch clamp studies on individual cells. Furthermore, until recently, it has not been possible to express sufficient amounts of α7 AChRs in human cell lines for functional assays. To obtain sufficient expression of α7 AChRs, we used chemical chaperones to promote assembly of human α7 in a cell line which co-expresses α7 and the AChR chaperone protein RIC-3 [25].

In this study, we examined the effects of acute and prolonged application of nicotine and three drugs which are known to inhibit nicotine self-administration (varenicline, cytisine and sazetidine-A), on human α4β2, α3β4 and α7 AChRs. These studies confirm and extend basic expectations of the properties of these agonists. The agonists fully desensitized these AChR subtypes with the exception of sazetidine-A on (α4β2)α4. We have defined the range of concentrations of each of these agonists which can sustain a nicotine that are sustained in smokers.

**Methods**

**cDNAs and Chemicals**

Human α3, α4, α7, β2 and β4 cDNAs were cloned in this laboratory as described previously [21,31,32]. Sazetidine-A was from Tocris Bioscience (Ellisville, MO). All other chemicals were from Sigma-Aldrich (St. Louis, MO).

**Cell Lines and Transfection**

The parental cell line used for transfections was tsA201, derived from the human embryonic kidney cell line (HEK) 293 [33]. The cell line permanently expressing α4β2 AChRs [22,23] has a mixture of two α4β2 stoichiometries, namely (α4β2)α4, which has lower sensitivity, and (α4β2)β2, which has higher sensitivity to activation by ACh [22]. The cell line permanently expressing α3β4 AChRs has been described [21,34]. A stable cell line expressing functional α7 AChRs was prepared by initially transfecting the tsA201 cell line with cDNA for α7 and subsequently transfecting with cDNA for the AChR-selective chaperone, human RIC-3. The expression of functional α7 AChRs in this cell line was further increased by growth in the chemical chaperones valproic acid (VPA, 1 mM) and 4-phenylbutyric acid (PBA, 3 mM) for at least 2 weeks before functional assays [25].

All transfected cell lines were grown in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (HyClone, Logan, UT) supplemented with 2 mM glutamine. The expression of α4, α3 and α7 was maintained with Zeocin (0.5 mg/ml) and the expression of β2, β4 and RIC-3 was maintained with G418 (0.6 mg/ml). The cell lines were grown at 37°C with 5% CO2 in a humidified atmosphere.

**Acute Activation**

Responses to nicotinic agonists were determined using a FLEXStation microplate fluorometer (Molecular Devices, Sunnyvale, CA) as described [23]. For cell lines expressing α4β2 and α3β4 AChRs, the cells were plated at 10^5 cells/ml (100 μl/well) in black-walled clear-bottom 96 well plates (Costar, Fisher Scientific, Pittsburgh, PA), and incubated for 48 hours prior to assay. Responses to various nicotinic agonists. The α7/RIC-3 expressing cells were plated at 5×10^3/ml in black-walled clear-bottom 96 well BioCoat plates (BD Biosciences, Franklin Lakes, NJ) in the continued presence of VPA and PBA, with the addition of 5% human AB serum (Pel-Freeze Biologicals, Rogers, AR) to further increase expression of α7 [35]. The cells were then grown for 24 hours prior to the assay.

To measure responses to various nicotinic agonists, 100 μl of a fluorescent dye which is sensitive to changes in membrane potential (Molecular Devices) was added to the wells. The dye was prepared according to the manufacturer’s instructions, with the addition of atropine (0.5 μM) to block muscarinic responses. The plates were then incubated at 37°C for one hour prior to the assay. Serial dilutions of agonists were then prepared in Hanks Balanced Salt Solution (HBSS) in V-shaped 96-well plates (Fisher Scientific Co, Pittsburgh, PA). Fluorescent responses were measured in the FLEX Station at 25°C, with an excitation wavelength of 530 nm and an emission wavelength of 565 nm. Various agonists (50 μl) were added after the first 20 seconds and responses were followed for 60–120 seconds.

**Chronic Desensitization**

To measure desensitization, plates were prepared as for agonist assays. Sixteen hours prior to the assay, serial dilutions of agonists, prepared in regular growth medium, were added to the plates. One hour before the assay, the membrane potential-sensitive fluorescent dye with 0.5 μM atropine was added to the wells. For α4β2 AChRs, responses were measured to 3 μM ACh (to detect responses of (α4β2)α4 AChRs and 100 μM ACh (to detect responses of both stoichiometries). For α3β4 and α7 AChRs, responses to saturating concentrations of ACh (1 mM for α3β4 and 10 μM for α7) were measured. Each data point represents the average of peak values for individual dose response curves from 4–8 wells.

**Expression of (α4β2)β2 AChRs**

To determine which stoichiometry of α4β2 AChRs was affected by sazetidine-A, we performed short term transfection of β2 subunits into the α4β2 expressing cell line. To increase the expression of the higher sensitivity (α4β2)β2 stoichiometry, the cell line expressing α4 and β2 was cotransfected with human β2 (pRc-CMV/Genetecin) using the FuGene6 transfection agent (Roche Diagnostics, Indianapolis, IN). On the following day,
Smoldering Activation following Acute Desensitization

Responses of α4β2, α3β4 and α7 AChRs to the acute application of ACh (100 μM), nicotine (16 μM), varenicline (4 μM), cytisine (16 μM) and sazetidine-A (62.5 μM) were measured using the FlexStation as described. Drug concentrations were selected because they gave maximum sustained responses to these agonists. Results were expressed as a percentage of maximum response to ACh. Responses were monitored for 10 minutes, and then specific antagonists were added and responses recorded for another two minutes. The antagonists were dihydrobenzothiazole (DHTB) (1 μM) for α4β2, mecamylamine (MCA) (10 μM) for α3β4 and methyllycaconitine (MLA) (10 μM) for α7. These concentrations of antagonists were selected because they were sufficient to inhibit responses to the tested agonists without causing activation themselves.

Statistics

Data were graphed using GraphPad Prism software. Non-linear models (sigmoidal dose-response with variable slope or two site competition) were used to fit the concentration response curves. The EC50 and IC50 were calculated from the curves. KaleidaGraph software was used to determine Hill slopes and standard errors of the EC50 and IC50.

Results

Acute Responses to Nicotinic Agonists

Acute responses of α4β2, α3β4 and α7 AChRs were tested after application of a range of concentrations of ACh, nicotine, varenicline, cytisine and sazetidine-A, using the FlexStation with an indicator which is sensitive to changes in membrane potential. Responses of these AChRs to saturating concentrations of ACh are shown in Figure 1. The kinetics of responses of the other agonists were very similar to those of ACh (data not shown). The effects of saturating concentrations of ACh on α4β2 and α3β4 AChRs had the same appearance, with a maximum response reached within 40 seconds of agonist application. The responses of α7 AChRs were quite different with a maximum response within 5 seconds, followed by rapid desensitization. However, the rate of acute desensitization was less than detected with electrophysiological techniques [36–38]. The amplitudes of responses of saturating concentrations of ACh (expressed as relative fluorescence units) were similar for α4β2 (167,000+/-18,000) and α3β4 (161,000+/-14,000), but significantly lower for α7 AChRs (54,000+/-3000), probably as a result of rapid desensitization [36].

The concentration response curves for various agonists on α4β2, α3β4 and α7 AChRs are shown in Figure 2. The EC50’s are summarized in Table 1. Nicotine had an efficacy comparable to that of ACh on α4β2 AChRs, whereas varenicline, cytisine and sazetidine-A were partial agonists, with efficacies of 48% for varenicline, 34% for cytisine and 44% for sazetidine-A. All of the tested compounds were full agonists on α3β4 and α7 AChRs. The EC50 values for α7 were lower than often reported by electrophysiological techniques. The EC50 values for α7 vary widely according to the assay method [36,39–41]. Millisecond agonist kinetics are probably irrelevant for drugs present in the body for hours. It is likely that sustained smoldering activation and sustained antagonism due to desensitization are the most relevant factors. The fluorescence indicator is a more sensitive measure of α7 activation, although the response kinetics are slower [39].

The cell line transfected with α4 and β2 subunits expresses a mixture of (α4)2β2 and α4β2, α4 stoichiometries, which have different sensitivities to nicotine and other agonists. The concentration response curves for acetylcholine, nicotine and varenicline fit with a two-site competition model, likely indicating that these agonists have different effects on the two stoichiometries. On the other hand, the dose response curves for cytisine and sazetidine-A were monophasic, likely because these agonists act on only one stoichiometry.

The EC50 of nicotine for the more sensitive (α4)2β2 stoichiometry was 0.18 μM, which is within the range of nicotine levels detected in smokers (see Discussion). For varenicline, the EC50 for the more sensitive stoichiometry was 0.20 μM, which is close to the peak blood levels of 0.1 μM detected in humans after a 1 mg dose of this drug [42]. On the other hand, the EC50 for nicotine on α3β4 was 9.7 μM and for α7 AChRs was 0.75 μM, levels which cannot be reached in the systemic circulation. The EC50 for varenicline on α7 AChRs was 0.4 μM, which is close to levels reached in humans after a dose of 1 mg [42]. The EC50 for cytisine for α4β2 AChRs was 5.5 μM. It is uncertain whether this is a clinically achievable level. Sazetidine-A was the most potent of all the agonists on α4β2 AChRs (EC50 = 0.0023 μM). In mice treated with 2 mg/kg sazetidine-A, serum levels of 1.6 μM and brain levels of 0.15 μM are reached [19].

Desensitization

To assess desensitization, cell lines expressing human AChRs were incubated overnight with a range of concentrations of agonists, and responses to ACh were then measured. For α4β2 AChRs, activity was assayed using 3 μM ACh to assay function of the more sensitive (α4)2β2 stoichiometry, and 100 μM ACh (to assay function of both stoichiometries). For the other AChRs, 0.5 μM nicotine was added to further increase the expression of the (α4)2β2β2 stoichiometry. After incubation for 24 hr with nicotine, the cells were washed twice with growth medium, and then serial dilutions of sazetidine-A were added for 6 hours prior to the assay. Desensitization by sazetidine-A was measured using the FlexStation as described, with 5 μM and 100 μM ACh.
saturating concentrations of ACh were applied (1.0 mM for α3β4 and 10 μM for α7). Responses for the three different AChRs are shown in Figures 3, 4, 5, 6, along with the dose response curves for activation (the same as shown in Figure 2). The range of concentrations at which both sustained activation and desensitization can occur ("smoldering activation") was calculated by multiplying the acute response to agonists at each concentration by the fractional response remaining after desensitization.

The results for α4β2 are shown in Figure 3. The intercept of the activation and desensitization curves is shown in Table 1. For nicotine, the area of overlap of the activation and desensitization curves was centered at 0.13 μM (summarized in Table 1). This is within the range of nicotine concentrations...
Table 1. Agonist Efficacy and Sensitivity for Activation and Desensitization.

<table>
<thead>
<tr>
<th>Activation EC50 (μM)</th>
<th>ACh</th>
<th>Nicotine</th>
<th>Varenicline</th>
<th>Cytisine</th>
<th>Sazetidine-A</th>
</tr>
</thead>
<tbody>
<tr>
<td>α4/2</td>
<td>Hill</td>
<td>Hill</td>
<td>Hill</td>
<td>Hill</td>
<td>Hill</td>
</tr>
<tr>
<td>α4/2 0.23±0.05</td>
<td>1.5</td>
<td>0.18±0.03</td>
<td>1.8</td>
<td>1.1</td>
<td>0.9</td>
</tr>
<tr>
<td>α4/2 51±35</td>
<td>1.3</td>
<td>4.2±0.5</td>
<td>2.5</td>
<td>6.1±0.2</td>
<td>1.8</td>
</tr>
<tr>
<td>α3/4</td>
<td>Hill</td>
<td>Hill</td>
<td>Hill</td>
<td>Hill</td>
<td>Hill</td>
</tr>
<tr>
<td>α3/4 50±36</td>
<td>1.8</td>
<td>9.7±1.3</td>
<td>1.1</td>
<td>1.4</td>
<td>1.3</td>
</tr>
<tr>
<td>α7</td>
<td>2.5±0.3</td>
<td>2.4</td>
<td>0.75±0.1</td>
<td>1.7</td>
<td>0.4±0.02</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.5±0.06</td>
</tr>
<tr>
<td>Efficacy (%) (relative to ACh)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4.3±0.08</td>
</tr>
<tr>
<td>α4/2</td>
<td>–</td>
<td>100</td>
<td>48</td>
<td>34</td>
<td>44</td>
</tr>
<tr>
<td>α3/4</td>
<td>–</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>α7</td>
<td>–</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Desensitization IC50 (μM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>α4/2: 3 μM ACh</td>
<td>–</td>
<td>0.04±0.004</td>
<td>–1.0</td>
<td>0.02±0.003</td>
<td>–0.6</td>
</tr>
<tr>
<td>α4/2: 100 μM ACh</td>
<td>–</td>
<td>5.0±1.0</td>
<td>–1.2</td>
<td>0.9±0.08</td>
<td>–1.0</td>
</tr>
<tr>
<td>α3/4: 1.0 mM ACh</td>
<td>–</td>
<td>9.1±1.3</td>
<td>–0.9</td>
<td>2.5±0.4</td>
<td>–1.1</td>
</tr>
<tr>
<td>α7: 10 μM ACh</td>
<td>–</td>
<td>3.4±0.18</td>
<td>–3.2</td>
<td>0.4±0.05</td>
<td>–2.6</td>
</tr>
<tr>
<td>Intercept of Activation and Desensitization Curves (μM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>α4/2: 3 μM ACh</td>
<td>–</td>
<td>0.13</td>
<td>0.16</td>
<td>0.45</td>
<td>0.0015</td>
</tr>
<tr>
<td>α4/2: 100 μM ACh</td>
<td>–</td>
<td>1.82</td>
<td>0.93</td>
<td>0.74</td>
<td>0.0002</td>
</tr>
<tr>
<td>α3/4: 1.0 mM ACh</td>
<td>–</td>
<td>8.7</td>
<td>2.1</td>
<td>4.1</td>
<td>2.2</td>
</tr>
<tr>
<td>α7: 10 μM ACh</td>
<td>–</td>
<td>1.7</td>
<td>0.4</td>
<td>2.1</td>
<td>1.5</td>
</tr>
</tbody>
</table>

The EC50's for activation of α4/2, α3/4 and α7 AChRs are expressed in μM. In cases where the dose response curves fit with a two-site competition model, the EC50 for the higher sensitivity component is listed first. For desensitization, cell lines expressing various human AChRs were incubated overnight in the presence of a range of concentrations of agonists, and then tested for activation by ACh. For α4/2 AChRs, two concentrations of ACh were tested, namely 3 μM (to test the more sensitive stoichiometry (α4/2)2 and 100 μM ACh (to assay function of both stoichiometries). For the other AChRs saturating concentrations of ACh were used (1.0 mM for α3/4 and 10 μM for α7).

doi:10.1371/journal.pone.0079653.t001

found in the blood of smokers (0.058–0.34 μM [43]). The extent of calculated smoldering activation at a clinically relevant concentration of 0.1 μM nicotine was 6% of maximum response for the (α4β2)2β2 stoichiometry and 18% for the (α4β2)2α4 stoichiometry. Nicotine is capable of sustaining a calculated desensitization curves for (α4/2)2 sites centered at 0.45 μM. For varenicline or cytisine is likely mediated by the (α4β2)2α4 stoichiometry. To resolve the contributions of the two stoichiometries to the effects of sazetidine-A, we transfected the (α4β2)2α4 expressing cell line with additional β2 subunits, and then cultured the cells in the presence of 0.5 μM nicotine in order to express predominantly the (α4β2)2α4 stoichiometry. As shown in Figure 4, the desensitization curves for sazetidine-A, using both 3 μM and 100 μM ACh overlapped. These curves are very similar to the one shown in Figure 3 for sazetidine-A on mixed stoichiometries of α4β2 tested with 3 μM ACh (which activates predominantly the (α4β2)2α4 stoichiometry). This indicates that sazetidine-A desensitizes only the (α4β2)2α4 stoichiometry. The plateau on the dose response curve for 100 μM ACh with mixed stoichiometries of α4β2* likely indicates a lack of agonist and desensitizing activity of sazetidine-A on the less sensitive (α4β2)2α4 stoichiometry. Carbone et al. [30] reported that sazetidine-A is a full agonist at (α4β2)2β2 AChRs but had <1% efficacy on the (α4β2)2α4 stoichiometry. Sazetidine-A may not be able to bind, activate or desensitize the third ACh binding site present at the α4/2* interface in the (α4β2)2α4 stoichiometry [45]. Sazetidine-A has by far the highest affinity of these agonists at the α4β2 binding sites and is exceptionally potent at inhibiting nicotine self-administration in rats [12]. This implies that
Figure 3. Activation and Desensitization of α4β2 AChRs by Various Agonists. Responses were measured using the FLEXStation with an indicator sensitive to changes in membrane potential. Results are expressed as a percentage of maximum fluorescence. Activity remaining after 16 hours desensitization by the indicated concentrations of agonist was assayed using 3 μM ACh (to assay function of the more sensitive stoichiometry (α4β2)β2), and 100 μM ACh (to assay function of both stoichiometries). Each data point is the average of the peak fluorescence of 4–8 dose-response curves. The responses to acute application of agonists are the same as shown in Figure 2. The extent of smoldering activation (shaded area) was
Inhibition of nicotine self-administration can be mediated by desensitizing \( \alpha_4\beta_2 \) AChR responses through their \( \alpha_4\beta_2 \) binding sites. The desensitizing effects of sazetidine-A are known to persist long after brief acute activation [44].

For all of the tested agonists, \( \alpha_3\beta_4 \) AChRs were much less sensitive to both activation and desensitization than were \( \alpha_4\beta_2 \) AChRs (Figure 5). The areas of overlap for the nicotine and varenicline activation and desensitization curves correspond to much higher drug levels than can be achieved in humans.

As shown in Figure 6, the activation and desensitization curves for \( \alpha_7 \) AChRs were much steeper than for either \( \alpha_4\beta_2 \) or \( \alpha_3\beta_4 \), as expected since \( \alpha_7 \) AChRs have five ACh binding sites acting cooperatively to activate this AChR (rather than two for \( \alpha_4\beta_2 \) and \( \alpha_3\beta_4 \), or three for \( \alpha_4\beta_2 \)). For nicotine, the area of overlap of the activation and desensitization curves for \( \alpha_7 \) corresponds to concentrations of nicotine that are much higher than can be reached in humans, with an intercept of the nicotine activation and desensitization curves of 1.7 \( \mu M \). However, for varenicline, the area of overlap of the activation and desensitization curves for \( \alpha_7 \) corresponds to concentrations that are within a clinically achievable range, with the intercept of the curves at 0.4 \( \mu M \).

**Smoldering Activation Following Acute Desensitization**

We evaluated the kinetics of responses over several minutes to concentrations of the various agonists that gave maximum sustained responses. The results were expressed as a percentage of the maximum response to ACh. As shown in Figure 7, for \( \alpha_4\beta_2 \) and \( \alpha_3\beta_4 \) AChRs, following acute activation and partial desensitization, there was a low level of sustained activation lasting at least 10 minutes. This sustained response was abrogated by the application of specific antagonists after 10 minutes (dihydroerythroidine (DHE) (1 \( \mu M \)) for \( \alpha_4\beta_2 \) or mecamylamine (MCA) (10 \( \mu M \)) for \( \alpha_3\beta_4 \)). For \( \alpha_7 \) AChRs, the initial activation and desensitization was more rapid than for \( \alpha_4\beta_2 \) or \( \alpha_3\beta_4 \) AChRs. The residual response after 10 minutes was abrogated by the application of the \( \alpha_7 \) antagonist methyllycaconitine (MLA) (10 \( \mu M \)).

Thus, small but significant smoldering responses can be maintained for a period of minutes after acute activation. With \( \alpha_3\beta_4 \) and \( \alpha_7 \) subtypes, these effects may not be significant at drug concentrations obtained in vivo. With \( \alpha_4\beta_2 \) subtypes, small but significant effects may occur in vivo, and may contribute to nicotine addiction.

**Discussion**

In this study, we utilize human AChRs cloned in human cells to examine the dual effects of activation and desensitization by nicotinic agonists. These transfected cell lines have advantages over AChRs expressed in Xenopus oocytes, which can retain nicotine and other agonists, and release them slowly, making it difficult to assess desensitization [45]. This is not an issue with HEK cells, which are much smaller than oocytes and lack their internal yolk compartments or other reservoirs that may account for tertiary amine uptake. Our binding studies with nicotine and epibatidine to live AChR-expressing HEK cells show that unbound agonists are easily washed away, indicating that these cells do not retain tertiary amines (unpublished results).

It has not previously been possible to measure function of \( \alpha_7 \), because levels of expression were too low for functional assays. We have overcome this limitation by co-transfection with RIC-5 and by the use of chemical chaperones [25]. Human cell lines expressing specific AChR subtypes can be used for screening and evaluating novel compounds with activity on these AChRs.

Although nicotine, varenicline, cytisine and sazetidine-A are all agonists, their behavioral effects may depend as much on desensitization as activation. Most *in vivo* studies of nicotinic agonists have examined the acute effects of these drugs over seconds to minutes. It is unclear how this relates to the *in vivo* setting, where the drugs are present for hours or days. If the major mechanism by which these partial agonists inhibit nicotine self-administration is desensitization, then this clinical effect may depend primarily on their binding affinity, rather than EC50 or efficacy.

Cytisine is a plant alkaloid used predominantly in Europe as an aid for smoking cessation [46]. It is a partial agonist on \( \alpha_4\beta_2 \) AChRs [47]. However, its clinical utility has been limited by poor absorption and limited brain penetration. Using cytisine as a lead compound, Coe et al. synthesized a series of \( \alpha_4\beta_2 \) partial agonists. One of these compounds, varenicline, was selected for further development because of its improved potency and efficacy [11]. Clinically, varenicline has been shown to improve long-term smoking cessation rates compared to unassisted quit attempts or bupropion (see [48] for review). It is now widely used for smoking cessation.

Sazetidine-A is a novel nicotinic receptor ligand that is highly selective for \( \alpha_4\beta_2 \) AChRs [44]. It has potential applications for treating nicotine addiction [12], as well as depression [13,16,49].
and pain [14,50]. Initially it was reported to desensitize α4β2 AChRs in the absence of activation, but did not appear to either activate or desensitize rat α3β4 AChRs [44]. However, subsequently Zwart et al. [51], using Xenopus oocytes expressing human α4 and β2 subunits, found that sazetidine-A was a potent agonist for both α4β2 stoichiometries. It was a full agonist on the (α4β2)2β2 stoichiometry but had only 6% activity on α4β2β4. Using pentameric concatenated (α4β2)2β2 and (α3β2)2α4 AChRs expressed in Xenopus oocytes, Carbone et al. [30] found that sazetidine-A was a full agonist on α4β2β2 but was a partial agonist with very low efficacy on α4β2β4 AChRs.

We found that varenicline, cytisine and sazetidine-A are partial agonists on the mixture of α4β2 AChRs in the absence of activation, but did not appear to either activate or desensitize rat α3β4 AChRs [44]. However, subsequently Zwart et al. [51], using Xenopus oocytes expressing human α4 and β2 subunits, found that sazetidine-A was a potent agonist for both α4β2 stoichiometries. It was a full agonist on the (α4β2)2β2 stoichiometry but had only 6% activity on α4β2β4. Using pentameric concatenated (α4β2)2β2 and (α3β2)2α4 AChRs expressed in Xenopus oocytes, Carbone et al. [30] found that sazetidine-A was a full agonist on α4β2β2 but was a partial agonist with very low efficacy on α4β2β4 AChRs.

We propose that the area of overlap of the activation and desensitization curves defines the range of concentrations over which smoldering activation can be sustained. For α4β2 AChRs, the range of smoldering activation for nicotine and varenicline corresponds to concentrations that can be achieved clinically. However, for nicotine, the range of smoldering activation for α3β4 and α7 AChRs exceeds concentrations that can be reached in humans. For varenicline the range of smoldering activation for α3β4 AChRs exceeds clinically achievable levels. However, for α7 the range of smoldering activation corresponds to drug levels that can be reached clinically. This suggests that varenicline may have a clinical effect on α7 AChRs, which could contribute to the undesirable side effects of this drug.
The α4β2 cell line has a mixture of (α4β2)2β2 and (α4β2)2α4 stoichiometries. In order to distinguish the effects of the two stoichiometries on the desensitization of α4β2 AChRs, we used two concentrations of ACh, namely 3 μM (to detect effects on the high sensitivity stoichiometry), and 100 μM (to detect effects on both stoichiometries). Recent reports indicate that the low sensitivity (α4β2)2α4 stoichiometry has a third ACh binding site at the interface between adjacent α4 subunits, resulting in an intrinsic bimodal concentration response curve with an additional low sensitivity component to the response [4,5]. Because we did not examine pure populations of (α4β2)2α4 AChRs, we were unable to detect this.

As expected, the agonist effect of nicotine on α4β2 AChRs was bimodal. For the more sensitive stoichiometry of α4β2, the EC50 for activation (0.18 μM) and the intercept of the activation and desensitization curves (0.13 μM) correspond to levels of nicotine that are clinically relevant (see below). On the other hand, the EC50’s and the intercepts of the activation and desensitization curves of nicotine for α3β4 and α7 AChRs are well above the range of concentrations that are achieved in smokers, indicating that these AChRs are unlikely to be involved with the reinforcing properties of nicotine. This is consistent with studies in transgenic mice showing that α7 does not contribute to nicotine self-administration, whereas the α4 and β2 subunits are both necessary and sufficient to maintain nicotine self-administration [6].

Apart from our results on (α4β2)2β2 for desensitization by sazetidine-A, we only examined mixed stoichiometries of α4β2. The selection of 3 and 100 μM ACh for desensitization of α4β2 AChRs may not completely separate the effects of the high and low sensitivity stoichiometries. While the use of chimeric or concatameric AChRs may separate the effects of the different stoichiometries of α4β2 AChRs, cell lines with a mixture of stoichiometries may be more representative of in vivo effects.

In active smokers, the majority of α4β2 AChRs in the brain are saturated [52], and thus are likely in a desensitized state. There is no information in humans on levels of nicotine in the brain during active smoking, but they are likely to be significantly higher than blood levels. Peak nicotine concentrations in venous blood of heavy smokers vary from 9.4–55.1 ng/ml (0.058–0.34 nM) [43].

At the clinically relevant nicotine concentration of 0.1 μM, the extent of smoldering activation was higher for (α4β2)2α4 (18%) than for (α4β2)2β2 (6%). This indicates that the stoichiometry
greater probability of channel opening when three ACh binding sites are occupied [4,5].

Our results show that cytisine is a partial agonist on \( \alpha4\beta2 \) and a full agonist on \( \alpha3\beta4 \) and \( \alpha7 \), confirming what others have found [53]. The EC50 for cytisine on \( \alpha4\beta2 \) was 5.3 \( \mu M \). It is uncertain whether this concentration is clinically relevant, as drug levels of cytisine that can be reached in humans are not yet defined [54]. Using concatameric as well as unlinked \( \alpha4\beta2 \) AChRs, Carbone et al. found that cytisine was a partial agonist on \( \alpha4\beta2\alpha4 \), but was inactive on \( \alpha4\beta2\beta2 \) [30].

Peak varenicline levels of 0.48 \( \mu M \) are reached after 14 days on a standard dose of 1 mg twice daily [55]. We found that the EC50 for the more sensitive stoichiometry of \( \alpha4\beta2 \) was 0.2 \( \mu M \), which is within the therapeutic range, accounting for the therapeutic efficacy of this drug in treating nicotine addiction. The EC50 for \( \alpha7 \) was 0.4 \( \mu M \), also within the therapeutic range. The effect of varenicline on \( \alpha7 \) AChRs may account for some of the toxicity of this drug. Nausea, which is a dose-limiting toxicity of varenicline, probably results from activation of \( 5HT_3 \) receptors [56]. The cause of the rare psychotic effects of varenicline which have led to the black box warning are unclear.

We found that sazetidine-A was a partial agonist on \( \alpha4\beta2 \) and a full agonist on \( \alpha3\beta4 \) and \( \alpha7 \) AChRs. It was highly selective for \( \alpha4\beta2 \) AChRs, with an EC50 of 0.023 \( \mu M \), compared with 0.17 \( \mu M \) for \( \alpha3\beta4 \) and 1.2 \( \mu M \) for \( \alpha7 \). However, using this fluorescence assay, we detected much greater activity of sazetidine-A on human \( \alpha3\beta4 \) and \( \alpha7 \) AChRs than did Liu et al. [57] with a rubidium efflux assay on rat \( \alpha3\beta4 \) and \( \alpha7 \) AChRs. Using transient transfection of \( \beta2 \) to the \( \alpha4\beta2 \) expressing cell line we were able to resolve the effects of sazetidine-A on the two \( \alpha4\beta2 \) stoichiometries. We found that sazetidine-A desensitizes only the \( \alpha4\beta2\beta2 \) stoichiometry. The differential effect on the two stoichiometries may explain the discrepant reports in the literature regarding whether or not sazetidine-A can activate \( \alpha4\beta2 \) AChRs.

The results reported here allow us to speculate on the effects of prolonged presence of these agonists on endogenous cholinergic signaling in vivo as well as modulation of the effects of nicotine in smokers. Since varenicline is a partial agonist with greater affinity than nicotine and consequently more potency at desensitizing, the smoldering activation produced by nicotine on \( \alpha4\beta2 \) AChRs will be reduced in the presence of varenicline. The net effect of varenicline will be antagonistic to both the effects of nicotine and endogenous ACh signaling.

Cytisine has lower efficacy than varenicline on \( \alpha4\beta2 \) but also has lower affinity and consequently less potency at desensitizing. The net effect of cytisine will be antagonistic to both the effects of nicotine and endogenous ACh signaling and it will decrease smoldering activation by nicotine.

Sazetidine is a partial agonist with much higher affinity than either varenicline or cytisine for \( \alpha4\beta2\beta2 \) and it does not desensitize \( \alpha4\beta2\alpha4 \). Therefore, it has a very potent net desensitizing effect on the \( \alpha4\beta2\beta2 \) stoichiometry while allowing nicotine to cause smoldering activation or desensitization of the \( \alpha4\beta2\alpha4 \) stoichiometry.

On \( \alpha3\beta4 \) AChRs, nicotine is expected to produce little activation or desensitization at concentrations typically sustained in smokers. Varenicline at submicromolar concentrations will also have limited effect. Cytisine should cause significant desensitization, but little agonist activity, at submicromolar concentrations. Sazetidine at submicromolar concentrations will cause significant smoldering activation as well as desensitization, thereby differing significantly from varenicline and cytisine.

On \( \alpha7 \) AChRs, nicotine at concentrations sustained in smokers should have little agonist or desensitizing effect. Varenicline should
cause significant smoldering activation and desensitizing effects at the concentrations used for smoking cessation therapy. This might contribute to the off target effects which have given it a black box warning of psychopathological effects in some smokers. Cytisine should have little effect on α7 at therapeutic doses. However, smoking cessation very substantially smoldering agonist effects on α7 concentrations that would be therapeutically significant. This could produce significant off target effects.

In summary, we have defined the range of concentrations of nicotinic agonists and partial agonists which can sustain smoldering activation of human α4β2, α3β4 and α7 AChRs. Further studies are needed to determine the role of smoldering activation not only in nicotine addiction but also in the therapeutic effects of nicotinic agonists and partial agonists.

Author Contributions
Conceived and designed the experiments: BC JL AK. Performed the experiments: BC AK. Analyzed the data: BC AK. Contributed reagents/materials/analysis tools: JL BC AK. Wrote the paper: BC JL AK.